0
Abstract: Slide Presentations |

SERUM DIAGNOSIS OF LUNG ADENOCARCINOMA USING SURFACE-ENHANCED LASER DESORPTION AND IONIZATION MASS SPECTROMETRY FREE TO VIEW

Xiaoyang Luo, MD*; Haiquan Chen, MD
Author and Funding Information

Department of Cardiothoracic Surgery, Fudan University Cancer Hospital and Shang, Shanghai, Peoples Rep of China


Chest


Chest. 2007;132(4_MeetingAbstracts):471b. doi:10.1378/chest.132.4_MeetingAbstracts.471b
Text Size: A A A
Published online

Abstract

PURPOSE: Lung adenocarcinoma is, at present, the most common malignancy in the world and its overall 5-year survival rate is disappointed, because most of the patients are diagnosed at advanced stage. Early diagnosis may improve the prognosis of patients with lung adenocarcinoma. Surface-Enhanced Laser Desorption and Ionization Mass Spectrometry (SELDI) is one of the currently used techniques to identify biomarkers for cancers. This study explored the application of serum SELDI proteomic patterns to distinguish lung adenocarcinoma patients from healthy individuals.

METHODS: In an attempt to improve on current approaches to the serological diagnosis of lung adenocarcinoma, we analyzed serum samples from patients with and without lung adenocarcinoma using surface-enhanced laser desorption and ionization (SELDI) protein chip mass spectrometry. Using a case-control study design, serum samples from 71 patients with surgically resectable lung adenocarcinoma were matched samples from 71 age- and sex-matched healthy controls. The spectra were generated on weak action exchange (WCX2) chips, and protein peaks clustering and classification analyses were made using Ciphergen Biomarker Wizard and Biomarker Pattern software, respectively.

RESULTS: Among the peaks identified by SELDI, the 5 most discriminating protein peaks at 4047.79±1.60, 4203.99±1.91, 4959.81±2.13, 5329.30±2.55 and 7760.12±4.11could differentiate patients with lung adenocarcinoma from healthy controls with sensitivity of 90.41%, 78.08%, 50.68%, 57.53% , 72.60% and specificity of 97.06%, 93.44%, 71.15%, 76.36%, 94.92% when the critical point was 2.5.

CONCLUSION: SELDI profiling of serum can be used to accurately differentiate patients with lung adenocarcinoma from healthy controls.

CLINICAL IMPLICATIONS: SELDI profiling of serum and may be a potential tool for the screening of lung adenocarcinoma with attractive value for the correct clinic decision.

DISCLOSURE: Xiaoyang Luo, None.

Tuesday, October 23, 2007

12:30 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543